Pages that link to "Q72535664"

The following pages link to Suppression of experimental autoimmune encephalomyelitis by cannabinoids (Q72535664):

Displaying 37 items.

• The endocannabinoid system as an emerging target of pharmacotherapy (Q24648473) (← links)
• Cannabinoids control spasticity and tremor in a multiple sclerosis model (Q28138564) (← links)
• The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain (Q28236298) (← links)
• COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord (Q33235278) (← links)
• Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke (Q33793559) (← links)
• Structural determinants for recognition and translocation by the anandamide transporter (Q33861497) (← links)
• Towards cannabinoid drugs--revisited. (Q33906007) (← links)
• Therapeutic potential of cannabinoids in CNS disease (Q33964721) (← links)
• Nonpsychotropic cannabinoid receptors regulate microglial cell migration. (Q34179008) (← links)
• The role of cannabinoids in neurodegenerative diseases (Q34268475) (← links)
• Cannabinoids and neuroprotection (Q34520143) (← links)
• Cannabinoid control of neuroinflammation related to multiple sclerosis (Q34583231) (← links)
• Multiple sclerosis may disrupt endocannabinoid brain protection mechanism (Q34597217) (← links)
• Cannabinoids and multiple sclerosis (Q34786839) (← links)
• Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 (Q34912871) (← links)
• Cannabinoids and neuroinflammation (Q35046205) (← links)
• Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases (Q35166600) (← links)
• Cannabinoids in multiple sclerosis: do they have a therapeutic role? (Q35629051) (← links)
• Cannabinoid-based drugs as anti-inflammatory therapeutics (Q36111923) (← links)
• The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids (Q36341688) (← links)
• Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor (Q36416340) (← links)
• Cannabis and endocannabinoid modulators: Therapeutic promises and challenges (Q36892931) (← links)
• The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis (Q36902277) (← links)
• Cannabinoid-induced immune suppression and modulation of antigen-presenting cells (Q37015392) (← links)
• G protein-coupled receptors as therapeutic targets for multiple sclerosis (Q37112554) (← links)
• Neuroprotective agents: Cannabinoids (Q37855122) (← links)
• Current Complementary and Alternative Therapies for Multiple Sclerosis (Q42692520) (← links)
• Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes (Q43611492) (← links)
• Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice (Q44397681) (← links)
• Cannabinoid influence on cytokine profile in multiple sclerosis (Q46524712) (← links)
• [Therapeutic use of cannabinoids in neurology]. (Q53854698) (← links)
• Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis (Q58775742) (← links)
• A Review of Herbal Therapy in Multiple Sclerosis (Q60925849) (← links)
• Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells (Q61479730) (← links)
• Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis (Q73336405) (← links)
• Cannabinoids and multiple sclerosis (Q81478365) (← links)
• Targeting Endocannabinoid Metabolism: an Arrow with Multiple Tips Against Multiple Sclerosis (Q98228200) (← links)